No title
The incidence of oropharyngeal cancer (OPC) is increasing in developed countries, and OPC is associated with human papillomavirus infection [1, 2]. Immunotherapies show promise as an end-stage treatment for immune-infiltrated tumours. They are only efficacious in 18% of patients leading to investigation of the immune compartment to comprehend which factors contribute to effective treatments. Anti-
